A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques.

Autor:	Lim SY; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Osuna CE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Best K; Merck Science Center, Cambridge, MA 02141, USA.; Los Alamos National Laboratory, Los Alamos, NM 87545, USA., Taylor R; BioCryst Pharmaceuticals, Birmingham, AL 35244, USA., Chen E; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Yoon G; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Kublin JL; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Schalk D; Wisconsin National Primate Research Center, Madison, WI 53715, USA., Schultz-Darken N; Wisconsin National Primate Research Center, Madison, WI 53715, USA., Capuano S; Wisconsin National Primate Research Center, Madison, WI 53715, USA., Safronetz D; National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, R3E 3R2 Manitoba, Canada., Luo M; National Microbiology Laboratory, 1015 Arlington Street, Winnipeg, R3E 3R2 Manitoba, Canada., MacLennan S; BioCryst Pharmaceuticals, Birmingham, AL 35244, USA., Mathis A; BioCryst Pharmaceuticals, Birmingham, AL 35244, USA., Babu YS; BioCryst Pharmaceuticals, Birmingham, AL 35244, USA., Sheridan WP; BioCryst Pharmaceuticals, Birmingham, AL 35244, USA., Perelson AS; Los Alamos National Laboratory, Los Alamos, NM 87545, USA., Whitney JB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. jwhitne2@bidmc.harvard.edu.; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Jazyk:	angličtina
Zdroj:	Science translational medicine [Sci Transl Med] 2020 Jun 10; Vol. 12 (547).
DOI:	10.1126/scitranslmed.aau9135
Abstrakt:	Zika virus infection in humans has been associated with serious reproductive and neurological complications. At present, no protective antiviral drug treatment is available. Here, we describe the testing and evaluation of the antiviral drug, galidesivir, against Zika virus infection in rhesus macaques. We conducted four preclinical studies in rhesus macaques to assess the safety, antiviral efficacy, and dosing strategies for galidesivir (BCX4430) against Zika virus infection. We treated 70 rhesus macaques infected by various routes with the Puerto Rico or Thai Zika virus isolates. We evaluated galidesivir administered as early as 90 min and as late as 72 hours after subcutaneous Zika virus infection and as late as 5 days after intravaginal infection. We evaluated the efficacy of a range of galidesivir doses with endpoints including Zika virus RNA in plasma, saliva, urine, and cerebrospinal fluid. Galidesivir dosing in rhesus macaques was safe and offered postexposure protection against Zika virus infection. Galidesivir exhibited favorable pharmacokinetics with no observed teratogenic effects in rats or rabbits at any dose tested. The antiviral efficacy of galidesivir observed in the blood and central nervous system of infected animals warrants continued evaluation of this compound for the treatment of flaviviral infections. (Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu